Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
In einem turbulenten Marktumfeld hat die Aktie von Mainz Biomed (NASDAQ: MYNZ) BV ein 52-Wochen-Tief erreicht und ist auf 6,12 US-Dollar gesunken. Das für innovative Krebsscreening-Technologien bekann ...
Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for ...
Mainz Biomed Announces Stock Split. BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
Benzinga Finance on MSN12d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( NASDAQ:MYNZ ) (“Mainz Biomed” or the“Company”), a molecular genetics diagnostic company specializing in the early ...
BERKELEY, USA – MAINZ, Deutschland – 29. November 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), („Mainz Biomed" oder das „Unternehmen"), ein molekulargenetisches ...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback